Operating Expenses: The sum of all operating expenses for the given industry.
Immunovant, Inc. (IMVT) had Operating Expenses of $282.71M for the most recently reported fiscal year, ending 2024-03-31.
| Income Statement Financials | |
-- |
|
$-259.34M |
|
-- |
|
-- |
|
|
Operating Expenses |
$282.71M |
$-282.71M |
|
$23.94M |
|
$-258.77M |
|
$-258.77M |
|
$-259.34M |
|
$-259.34M |
|
$-259.34M |
|
$-259.34M |
|
$-282.71M |
|
$-282.48M |
|
138.10M |
|
138.10M |
|
$-1.88 |
|
$-1.88 |
|
| Balance Sheet Financials | |
$665.77M |
|
$0.46M |
|
$0.59M |
|
$666.37M |
|
$48.61M |
|
-- |
|
-- |
|
$48.61M |
|
$617.76M |
|
$617.76M |
|
$617.76M |
|
145.58M |
|
| Cash Flow Statement Financials | |
$-214.23M |
|
$-0.36M |
|
$472.43M |
|
$376.53M |
|
$635.37M |
|
$258.83M |
|
$41.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-214.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-41.98% |
|
-41.98% |
|
-38.92% |
|
-41.98% |
|
$4.24 |
|
$-1.55 |
|
$-1.55 |
|